hai MVA- Modified Vaccinia Ankara Conferences | Meetings | Events | Symposiums | ConferenceSeries

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

 

Recommended Conferences for MVA- Modified Vaccinia Ankara

MVA- Modified Vaccinia Ankara


As per available reports about 17 open access articles, 28 conferences, 3 national symposiums are presently dedicated exclusively to MVA and about 13 speakers gave presentations on MVA.

The Modified Vaccinia Ankara (MVA) is an attenuated vaccine of a poxvirus. It was licensed and used as a poxvirus vaccine in Bavaria and is a vector for vaccination against non-poxvirus diseases. Vaccinia viruses re-engineered to express foreign genes are vectors for production of recombinant proteins, the most common being a vaccine delivery system for antigens. Concerns about the safety of the vaccinia virus have been addressed by the development of vectors based on attenuated vaccinia viruses. One of them, the Modified Vaccinia Ankara (MVA') virus, is a highly attenuated strain of vaccinia virus that was developed towards the end of the campaign for the eradication of smallpox by Anton Mayr in Germany. Produced by more than 500 passages of vaccinia virus in chicken cells (chicken embryo fibroblast, MVA has lost about 10% of the vaccinia genome and with it the ability to replicate efficiently in primate cells. A recombinant MVA-based vector for vaccination with different fluorescent reporter genes was developed by Antonio Siccardi, which indicate the progress of genetic recombination with the transgene of an antigen

OMICS International 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies  and Publishes 700+ Open access journals Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

MVA is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile. MVA has been administered to numerous animal species including monkeys, mice, swine, sheep, cattle, horses, and elephants, with no local or systemic adverse effects. Over 120,000 humans have been safely and successfully vaccinated against smallpox with MVA by intradermal, subcutaneous, or intramuscular injections. Currently, the use of MVA as a recombinant HIV vaccine (MVA-B) is being tested in approximately 300 volunteers in several Phase I studies conducted by the International AIDS Vaccine Initiative. Studies in mice and nonhuman primates have further demonstrated the safety of MVA under conditions of immune suppression. Compared to replicating vaccinia viruses, MVA provides similar or higher levels of recombinant gene expression even in non-permissive cells. Recently, vaccination with smallpox vaccine (a vaccinia virus related to MVA) has been shown, on rare occasions, to cause heart problems in people who received it: heart inflammation (myocarditis), inflammation of the membrane covering the heart (pericarditis), and a combination of these two problems (myopericarditis). A few cases of cardiac chest pain (angina) and heart attack have also been reported following smallpox vaccination. It is not known at this time if smallpox vaccination causes angina or heart attacks. MVA is an attenuated vaccinia virus and does not replicate in the human body as efficiently as vaccinia. However. Whether or not MVA can induce the same side effects as vaccinia is not known at this time.

Relevant Conferences:

  1.  7th Vaccines & Vaccination Conference, September 28-30, 2015 Dubai, UAE
  2. 9th Vaccines & Vaccination Conference,                                                     November 30-December 02, 2015 San Francisco, USA
  3. 10th Vaccines & Vaccination Conference, June 16-18, 2016 Rome, Italy
  4. 13th Vaccines & Vaccination Conference,                                                   November 10-12, 2016 Melbourne, Australia
  5. 2nd Applied Microbiology Conference,                                                          October 31-November 02, 2016 Istanbul, Turkey
  6. Hepatitis Vaccines Conference June 16-18, 2016 Rome, Italy
  7. Virulant HIV Vaccines conference Oct 3-5, 2016 Miami, USA
  8. Children Vaccines Conference, Oct 10-12, 2016 Rome, Italy
  9. Cardio Vascular Medicine Conference, April 04-06, 2016 Philadelphia, USA  
  10. 8th Cardiologists Conference  July 18-20, 2016 Berlin, Germany 
  11. 2nd Infectious Diseases conference, August 25-27, 2016 Philadelphia, USA 
  12. 2nd Retroviruses & Novel Drugs conference                                                      June 30-July 01, 2016 Cape Town, South Africa 
  13. Infection Control  conference, Aug 1-2, 2016 Frankfurt, Germany 
  14. 2nd Antibodies conference, July 14-15, 2016 Philadelphia, USA 
  15. 4th Immunology conference September 28-30, 2015 Houston, Texas, USA
  16. World Vaccine Congress, 9 - 11 November 2015 Silken Puerta América, Madrid
  17. ICVV 2016 : 18th International Conference on Vaccines and Vaccination, September 15 - 16, 2016 "Hotel Mediterraneo Via Cavour, Rome, Italy
  18. Skin Vaccination Summit,                                                                                     2-4 September 2015 University of Lausanne CHUV, Lausanne, Switzerland
  19. Influenza Vaccines for the World, 6-9 October 2015 Algarve, Portugal
  20. The 2015 Vaccine Summit,                                                                                  13th - 15th October 2015 Cineworld: The O2, Peninsula Square, London
  21. Conference on 3Rs Alternatives and Consistency Testing in Vaccine Lot Release Testing, 16 -18 September 2015 Hotel Zuiderduin, The Netherlands
  22. Meningitis and Septicaemia in Children and Adults,                                                4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom

Relevant Societies :

  1. International Society of Vaccines
  2. International Society of DNA Vaccines
  3. Idaho Humane Society
  4. Ecuadorian Society of Medical Technologists Laboratory (SOTEMELAB)
  5. Infectious Diseases Society of America
  6. International Society for Infectious Diseases
  7.  Southern African HIV Clinicians Society
  8. Australian Federation Aids Organizations
  9. ANTIAIDS Foundation
  10. Apparel Lesotho Alliance to fight AIDS
  11. AIDS Action Committee of Massachusetts
  12. AIDS Foundation Houston
  13. Infectious Diseases Society of America (IDSA)
  14. Antimicrobial resistance - Royal Society

Relevant Companies:

  1. Dano Vaccines & Biologicals Pvt. Ltd.
  2. Ranbaxy Labs Ltd.
  3. Shanhta Biotech
  4. Novartis
  5. Pfizer
  6. Sanofi
  7. Merck
  8. Alcon.
  9. Bargn Farmaceutici Phils Co
  10. Barr
  11. Basi
  12.  Bausch & Lomb
  13. Baxalta
  14. Baxter International
  15.  Bayer Schering Pharma AG
  16.  Novartis
  17.  Novo Nordisk
  18.  Pfizer
  19.  Roche
  20.  Sunpharma
  21.  Sanofi
  22. Vaxgen

This page will be updated regularly.

This page was last updated on December 24, 2024

Conference Series Destinations